- Home
- LILAK vs ELVN Comparison
LILAK vs ELVN Comparison
Compare LILAK & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- ELVN
- Stock Information
- Founded
- LILAK 2017
- ELVN 2016
- Country
- LILAK Bermuda
- ELVN United States
- Employees
- LILAK N/A
- ELVN N/A
- Industry
- LILAK Cable & Other Pay Television Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- ELVN Health Care
- Exchange
- LILAK Nasdaq
- ELVN Nasdaq
- Market Cap
- LILAK 1.1B
- ELVN 927.8M
- IPO Year
- LILAK N/A
- ELVN 2020
- Fundamental
- Price
- LILAK $5.74
- ELVN $21.30
- Analyst Decision
- LILAK Buy
- ELVN Strong Buy
- Analyst Count
- LILAK 3
- ELVN 5
- Target Price
- LILAK $10.27
- ELVN $39.60
- AVG Volume (30 Days)
- LILAK 910.4K
- ELVN 610.1K
- Earning Date
- LILAK 08-05-2025
- ELVN 08-12-2025
- Dividend Yield
- LILAK N/A
- ELVN N/A
- EPS Growth
- LILAK N/A
- ELVN N/A
- EPS
- LILAK N/A
- ELVN N/A
- Revenue
- LILAK $4,441,000,000.00
- ELVN N/A
- Revenue This Year
- LILAK $2.45
- ELVN N/A
- Revenue Next Year
- LILAK $3.11
- ELVN N/A
- P/E Ratio
- LILAK N/A
- ELVN N/A
- Revenue Growth
- LILAK N/A
- ELVN N/A
- 52 Week Low
- LILAK $4.23
- ELVN $13.30
- 52 Week High
- LILAK $10.93
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LILAK 61.02
- ELVN 55.53
- Support Level
- LILAK $5.33
- ELVN $18.53
- Resistance Level
- LILAK $5.71
- ELVN $24.11
- Average True Range (ATR)
- LILAK 0.20
- ELVN 1.96
- MACD
- LILAK 0.07
- ELVN 0.15
- Stochastic Oscillator
- LILAK 87.18
- ELVN 55.68
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.